First-quarter cash-outs tumble 87 percent to $282.7 million versus $2.2 billion for the same period in 2007.
|
Seattle, Los Angeles and Washington D.C., which have cleared the billion-dollar funding mark, are on the fast track, survey finds.
|
Israeli security startup becomes latest grab in ongoing acquisition frenzy, coming after companies spent $1.28 billion to purchase 25 VC-backed security firms in 2007.
|
Based on trailing 12-month performance, funds post an 8.8 percent increase compared with the previous quarter.
|
Fundraising for 2007 hits $34.7 billion, the highest since 2001, according to a new survey.
|
Fourth quarter pushes venture-backed issues to $10 billion in 2007, double the 2006 take, but the M&A door has swung shut. In the final quarter, only 45 venture-backed M&A deals were completed, the least since the first quarter of 1998.
|
Fast-climbing clean tech helps staples IT and biotechnology put 2007 on pace to notch up the highest funding levels since 2001, surveys say.
|
Number of new funds in third quarter plummets 50 percent to smallest total in more than a decade.
|
Venture capital outperformed U.S. stock markets over last year, but funds turned in lackluster results in the first quarter, new data shows.
|
M&A deals ebb, but value of stock debuts climbs 212% to $4.3B
|
Late-stage funding shows strong growth in the third quarter.
|
As losses narrow for five-year returns, VCs focus on IPO climate.
|
Private equity giant raising $15 billion for U.S. buyouts.
|
Second report confirms venture investments in second quarter reached four-year high.
|
Revenue fell below expectations partly from slow Mac sales, but profits rose 41 percent.
|
Communications giant expects flat or low single-digit growth as opposed to mid-single-digit growth.
|
Lower-than-anticipated sales of biotech giant’s cancer drug disappoint Wall Street.
|
Biggest public pension fund and major venture investor doubles its assets in less than a decade.
|
With its MCI preoccupation ending, carrier has plans to focus on building its wireless strength, perhaps through acquisition.
|
Stung by falling sales, the pharma giant withdraws its 2006 and 2007 guidance.
|
Page
1
of
2
|